Filing Flows › 8-K events › Microbot Medical
Microbot Medical: regulation fd disclosure
Form 8-K filed Nov 5, 2026 · items 7.01, 8.01
FDA decisionsMicrobot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion
What the filing says
Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion HINGHAM, Mass., November 5, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that the Canadia
Read the filing on SEC EDGAR →
What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →
Microbot Medical at a glance
Microbot Medical, Q2 2026: revenue $241K. The chart follows the revenue to costs, profit and cash.
Microbot Medical: every quarter, Q/Q and Y/Y, holders and guidance →
Microbot Medical’s other material 8-Ks
- Oct 27, 2026 — FDA decisions Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Ro
- Oct 23, 2026 — FDA decisions Microbot Medical ® Attending Key Medical Conference to Engage with Decisionmakers as it Continues to
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
- Schrodinger Nov 4, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.